O'Grady H, Kelly C, Bouchier-Hayes D, Leahy A
Department of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland.
Br J Surg. 2002 Jul;89(7):838-44. doi: 10.1046/j.1365-2168.2002.02108.x.
An increased plasma level of homocysteine has been proposed as an independent risk factor for atherosclerosis; this review examines the evidence.
A Medline search was undertaken for English language articles on homocysteine and vascular disease. Further papers were identified by cross-referencing from the reference lists of relevant major articles.
Although much interest has been generated about homocysteine and atherosclerotic disease, contradictory data exist regarding its role in disease progression. There is insufficient current evidence to regard increased homocysteine level as a causative factor in atherosclerotic disease.
It is not known whether lowering plasma homocysteine concentration will reduce cardiovascular risk in the long term. Until such data become available, there is no evidence for the widespread use of folic acid therapy to reduce cardiovascular disease risk.
血浆同型半胱氨酸水平升高被认为是动脉粥样硬化的一个独立危险因素;本综述对相关证据进行了研究。
通过检索Medline数据库查找有关同型半胱氨酸与血管疾病的英文文章。通过对相关主要文章参考文献列表进行交叉引用确定了更多论文。
尽管同型半胱氨酸与动脉粥样硬化疾病引起了很多关注,但关于其在疾病进展中的作用存在相互矛盾的数据。目前没有足够的证据将同型半胱氨酸水平升高视为动脉粥样硬化疾病的致病因素。
目前尚不清楚长期降低血浆同型半胱氨酸浓度是否会降低心血管风险。在获得此类数据之前,没有证据支持广泛使用叶酸疗法来降低心血管疾病风险。